Background: Guidelines of heart failure therapy include cardiac resynchronization as
Introduction
Implantation of a cardiac resynchronization therapy (CRT) device is standard of care in the therapy of heart failure patients with severely depressed left ventricular function and a wide QRS complex. Several randomized controlled trials have shown remarkable benefits of CRT regarding mortality and morbidity in combination with an implantable cardioverterdefibrillator (ICD) but also with a stand-alone pacemaker [1, 2] . Many patients present with left ventricular ejection fraction (LVEF) below 35%, and thus are implanted with a CRT defibrillator (CRT-D). However, no strong evidence suggests that CRT-D must be used in all patients that are CRT candidates [3] . A relevant number of patients have severe comorbidities and die early after implant. Therefore, might not be in need of the ICD component of a CRT-D [4, 5] . Identification of such patients is considered important, as death as the competing event obviously precludes potential long-term benefit from the ICD component of CRT. Data regarding first-ever ICD therapy are conflicting; studies have shown both linear and asymptotic event curves [6] [7] [8] . The aim of this study was to determine independent predictors for early occurrence of both death and first-ever ICD therapy. If meaningful and/or highly prevalent predictors were identified, they could help in decision making for CRT-D or for CRT-P.
Methods
The study population consisted of all consecutive patients in whom a CRT-D was Chicago, IL).
The study is a retrospective merged analysis of data collected prospectively in both centres.
Results

Baseline characteristics and follow-up
A merged population of 904 patients was predominantly male (77%), had a mean age of 63 ± 11 years at implant and a primary prevention indication in 80%. Mean follow-up was 55 ± 38 months. Table 1 depicts all relevant baseline characteristics in detail. Figure 1 shows a flow chart of patients included in the study, mortality rate and mode of death, the arrhythmias treated by the ICD, and their separation into early or non-early events.
ICD therapies
During follow-up, 256 (28%) patients had ICD therapies. The first-ever event occurred early in 134 (52%) patients. In 2/3 ICD, therapy was delivered in the VT zone (82% of them occurring early), in 1/3, in the VF zone of the ICD (77% of them occurring early).
Independent predictors for early ICD therapy were secondary prevention (OR 3.21, 1.84-5.56, 0.01) and renal failure (OR 2.08, 1.24-3.50, 0.01). More detailed data is presented in Tables 2 and 3 . Independent predictors for VT as compared to fast VT/VF were beta-blocker therapy (OR 1.77, 1.09-2.86, 0.02) and increasing hemoglobin level (HR per g/L 1.02, 1.01-1.04, 0.01).
Mortality
Overall, 270 (30%) patients died after a mean 41 ± 31 months, mostly from advancing heart failure (41%) or non-cardiac causes (18%). Of note, the cause of death (not the time of death) was not recorded in the dataset in 33%. 141 (52%) patients had died within the first 3 years were thus, early. Independent predictors for early mortality were a history of percutaneous coronary intervention (PCI) (OR 2.01, 1.10-3.66, 0.02) and peripheral vascular disease (PVD) (OR 2.91, 1.08-7.87, 0.04). However, only 24% of patients had a history of PCI and 7% of PVD. A more detailed overview is shown in Table 4 .
Discussion
During a mean follow-up of more than 5.5 years, only 28% of these CRT-D patients had appropriate ICD therapies. The first-ever event occurred early in 52%. A third of them were delivered for potentially life-threatening arrhythmias. This rate is slightly lower than the mortality of these severely sick patients (50% renal failure, 66% in the New York Heart Association [NYHA] class III or ambulatory class IV). With the inclusion of 33 parameters to study early ICD therapy and early mortality, it was determined that secondary prevention and renal failure were predictors for early ICD therapy and history of PCI and PVD for early mortality.
It would be both scientifically intriguing and clinically helpful to identify those patients who either die early after ICD implantation (and in whom CRT-D implantation can be questioned and CRT-P offered) or those who never experience ICD therapies. It is thus not surprising that several studies have been undertaken with the focus of early mortality [4, 6, 10, 11] . In the present study only history of PCI and PVD were identified as predictors for early mortality, i.e. at 3 years. However, the clinical application of them has to be questioned, as they were present in only 24% and 7% of patients, respectively. In addition, a sub-analysis from MADIT-CRT showed that a history of PCI, independent of frequency or timing before enrolment, did not influence mortality [12] . Finally, there is no intuitive explanation for these two identified predictors and, due to the low number of patients with these comorbidities, a type I error especially for PVD cannot be excluded. In summary, this study failed to fulfil the particular aim of predicting early mortality in a clinically applicable way.
In CRT-D patients, no similar data are available to date. In a large ICD only cohort study with a validation cohort (total patient number 2700, 75% primary prevention) [10] , four factors predicted mortality at 1 year. They were PVD, age > 70 years, LVEF < 20% and creatinine > 176 mmol/L. Patients with only one factor had a mortality of 4% as compared to 18% in those with four factors. Results were confirmed in a population of 800 patients (100% primary prevention, 28% CRT-D) [4] . Age (here: > 75 years), impaired renal function (here:
GFR < 30 mL/min/1.73 m 2 ), QRS width > 120 ms, and atrial fibrillation were the four predictors. Mortality at 1 year was 2.5% in patients with 0 or 1 risk factors, but 46% in those with all four factors present. However, both papers do not discuss the fact that only 2% of patients were labelled as very high-risk patients, which renders the usefulness of these impressive results less applicable in daily life.
In a study of 225 octogenarians, LVEF < 20% and lack of beta-blocker therapy were the only two predictors of mortality at 1 year. Mortality of patients with LVEF < 20% was threefold compared to those with LVEF > 20%, but the patient number at risk are not mentioned, thus severely limiting this statement. Finally, the Italian IRIDE registry [6] reported their results on 600 patients with primary prevention (43% CRT-D). They showed a linear increase of mortality to 24% at 4 years, which is similar to the present results. This is surprising, given the much higher disease burden in the current study (48% renal failure and 71% NYHA class III/IV vs. 11% and 38%, respectively). In addition, even though ICD programing is comparable, the rate of ICD therapies was as high as 50% after 5 years, as opposed to 28% in the study herein.
Other factors are also not especially analyzed in this paper, as e.g. metabolic syndrome
with or without obesity, were not shown to influence mortality [13] .
To identify predictors of ICD therapy, early or rather late after implantation, is less useful in daily life. This is because a) there are data [7] showing that a substantial proportion of patients have their first ICD therapy after 5 years and b) especially in secondary prevention guidelines regarding continuation of ICD treatment even in patients without ICD therapy for many years are clear-cut. Nevertheless, this issue is being investigating. In the present CRT-D population, only two predictors could be identified (after analysing 33 parameters) for early ICD therapy, secondary prevention (which is commonly known) and renal failure. A Dutch cohort study [8] did not find a predictor using eight parameters. Identifying predictors that somehow "protect" patients from early or late ICD therapy seems alluring at first glance, as one could argue that such a patient might not be in need of the ICD part of CRT. Further studies especially in patients with dilated cardiomyopathy are needed that include parameters not included in the present dataset such as a true left bundle branch block as compared to other forms of QRS widening or late gadolinium enhancement as seen on magnetic resonance imaging.
Limitations of the study
This study has all the limitations of a retrospective database study. There was no "control group" with patients with only CRT-P, who might have had other predictors for early death other than CRT-D patients. Some data had to be imputed. Finally, about 10% were lost to follow-up, and in about the same percentage, the mode of death was unknown. This does, however, not influence prediction of early mortality, as the analysis was performed regarding all-cause mortality.
Conclusions
Predictors for early mortality after CRT-D implantation were a history of PCI and PVD, however present in only a minority of patients. A survey of the available literature suggests that it is difficult to predict early mortality, albeit this would impact on those patients with a high chance of dying and have no benefit from the ICD part of CRT.
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